Pomalidomide Medicine 06 June 2023 Extended indication Treatment of adult patients with relapsed and refractory multiple myeloma in combination with dexamethasone Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Pomalidomide Domain Hematology Reason of inclusion Generic G Main indication Multiple Myeloma Extended indication Treatment of adult patients with relapsed and refractory multiple myeloma in combination with dexamethasone Current proprietary name Imnovid Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Immunosuppression Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Immuunmodulator/proteasoom inhibitor. Fabrikant Celgene Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date March 2023 Expected Registration April 2024 Orphan drug Yes Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Marktexclusiviteit verloopt op 8 augustus 2023 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks